Streetbeat News

Products Services

NOK

Nokia, BT Group, and MediaTek have successfully completed trials of 5G Reduced Capability (RedCap) technology with RedCap devices. The trial took place at BT Group’s Adastral Park site, utilizing Nokia’s AirScale RAN portfolio, EE’s 5G Standalone (SA) network, and MediaTek’s RedCap testing platform. RedCap technology simplifies 5G devices, particularly small IoT devices, and optimizes their power efficiency. BT Group is evaluating RedCap to support new 5G use cases.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:34 am

HON

Honeywell International Inc (HON) has released a positive Global Business Aviation Outlook, indicating strong global demand for new business jets. The company expects new business jet deliveries to increase by 10% Y/Y in 2024, with expenditure growth of 13% Y/Y. However, Honeywell anticipates a decline in global flight activity in 2023 due to inflation and the resumption of commercial air service. The company also notes a slowdown in new jet orders as OEMs accelerate production rates to meet current demand.

Portfolio Pulse from Lekha Gupta

October 16, 2023 | 11:32 am

OMER

Omeros Corporation has decided to discontinue the ARTEMIS-IGAN trial as it did not reach statistical significance on the primary endpoint of reduction in proteinuria compared to placebo.

Portfolio Pulse from Bill Haddad

October 16, 2023 | 11:32 am

BABA

BIDU

COST

KWEB

WMT

Alibaba's stock is trading lower, in line with the broader index KraneShares CSI China Internet ETF, due to reports of tighter U.S. curbs on technology exports to China and the escalating Israel-Hamas conflict. The U.S. is considering stricter regulations on selling graphics chips for AI purposes and advanced chip-making equipment to Chinese companies, which could impact Alibaba's AI ambitions. However, Alibaba's Freshippo supermarket chain plans to transform approximately 350 offline stores into discount supermarkets by 2024, potentially boosting its market share.

Portfolio Pulse from Anusuya Lahiri

October 16, 2023 | 11:32 am

BOLT

Bolt Biotherapeutics has announced that updated clinical data from its Phase 1/2 dose-escalation study of BDC-1001 will be presented at the European Society for Medical Oncology Congress 2023.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:31 am

CFRX

ContraFect has received FDA clearance for its Investigational New Drug (IND) application for CF-370, allowing it to proceed with Phase 1 clinical trials.

Portfolio Pulse from Bill Haddad

October 16, 2023 | 11:31 am

KMDA

Kamada has announced several recent achievements related to Cytogam, a drug used for the prevention of Cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas, and heart.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:25 am

EXAI

Exscientia announced that two abstracts will be presented at the European Society for Medical Oncology Congress 2023. The abstracts demonstrate the preclinical efficacy of LSD1 inhibitor in primary AML samples and the potential of LSD1 inhibitor with AML standard of care therapies. They also show tumor growth inhibition through MALT1 in monotherapy and combination while lowering bilirubin toxicity risk.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:24 am

TRVN

Trevena has reported positive topline safety and tolerability data for the two Phase 1 proof-of-concept studies of TRV045. The results were consistent with prior first-in-human study, with no drug-related adverse events, serious adverse events, lymphopenia, bradycardia, or change in blood pressure reported.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:22 am

XAIR

Beyond Air has received an Innovative Technology contract from Vizient for its LungFit PH system. This contract will likely increase the accessibility and adoption of the LungFit PH system in hospitals and healthcare facilities that are members of Vizient.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:20 am